Key facts
- This page summarizes Deirdre P. Connelly's Form 4 filing for Sarepta Therapeutics, Inc. (SRPT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Sep 2024, 20:05.
Deirdre P. Connelly - 12 Sep 2024 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)
- Reporting relationship
- Director
- Issuer ticker
- SRPT
- Reported as of
- 12 Sep 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Sep 2024, 20:05:03 UTC
- Prior SEC filing
- 01 Jul 2024
- Next SEC filing
- 02 Oct 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ryan Brown as Attorney-in-Fact for Deirdre Connelly
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Deirdre P. Connelly filed Form 4 for Sarepta Therapeutics, Inc. (SRPT) on 16 Sep 2024.
Change
- Previous filing in this sequence was filed on 01 Jul 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SRPT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +2,842
- Change %
- Price
- $0.000000
- Shares after
- 2,842
- Date
- 12 Sep 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SRPT
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +6,442
- Change %
- Price
- $0.000000
- Shares after
- 6,442
- Date
- 12 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,442
- Exercise price
- $125.34
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs vest in three equal annual installments beginning September 12, 2025.
Footnote F2
The option vests in three equal annual installments beginning September 12, 2025.